Can Mounjaro Cause Hair Loss? Evidence and Management

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes mellitus. Whilst the medication effectively improves glycaemic control and facilitates significant weight reduction, some patients have reported hair thinning during treatment. Understanding whether Mounjaro can cause hair loss requires examining both clinical trial data and the indirect effects of rapid weight loss. This article explores the evidence linking Mounjaro to hair changes, the mechanisms that may explain this association, and practical strategies for managing hair health whilst taking this medication. If you experience concerning hair loss, appropriate medical evaluation can identify reversible causes and guide management.

Understanding Mounjaro and Its Primary Effects

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus. It belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.

The mechanism of action involves mimicking two naturally occurring incretin hormones that regulate blood glucose and appetite. By activating both GIP and GLP-1 receptors, Mounjaro enhances insulin secretion when blood glucose levels are elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite. These combined effects lead to improved glycaemic control in people with type 2 diabetes and significant weight reduction.

Mounjaro is administered as a once-weekly subcutaneous injection, with doses typically starting at 2.5 mg and gradually increasing to a maintenance dose of 5 mg, 10 mg, or 15 mg, depending on individual response and tolerability. Clinical trials have demonstrated substantial weight loss—with average reductions of 15-20% in people without diabetes and somewhat lower in those with type 2 diabetes—alongside improvements in cardiovascular risk factors.

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation. These effects are generally mild to moderate and tend to diminish over time. Important safety considerations include risk of acute pancreatitis (seek urgent medical attention for severe, persistent abdominal pain), gallbladder disease, dehydration and acute kidney injury (particularly with vomiting or diarrhoea), and potential worsening of diabetic retinopathy in some patients with rapid improvement in blood glucose. Hypoglycaemia may occur, especially when combined with insulin or sulphonylureas. The UK product information also includes precautionary information about thyroid C-cell tumours based on animal studies, though a causal relationship in humans has not been established. Understanding these primary effects provides essential context when considering other potential side effects, including changes to hair growth.

Can Mounjaro Cause Hair Loss? What the Evidence Shows

Hair loss, medically termed alopecia, has been reported by some individuals taking Mounjaro. In the pivotal SURMOUNT clinical trial programme evaluating tirzepatide for weight management, alopecia was reported more frequently in participants receiving tirzepatide compared to placebo, though at relatively low rates. The European Medicines Agency's assessment report notes that alopecia was observed in clinical trials, particularly in the context of substantial weight loss.

However, there is no established direct pharmacological mechanism by which tirzepatide would cause hair loss. The drug's action on GIP and GLP-1 receptors does not directly affect hair follicle biology or the hair growth cycle. This distinguishes it from certain medications known to cause drug-induced alopecia through direct follicular toxicity.

What appears more likely is that hair changes observed during Mounjaro treatment are indirect consequences related to the medication's primary effects—particularly rapid and substantial weight loss, metabolic changes, and potential nutritional alterations. This pattern mirrors observations with other GLP-1 receptor agonists and weight loss interventions more broadly.

It is crucial to note that establishing causality between any medication and hair loss can be challenging, as numerous factors influence hair health. Whilst some patients may experience temporal association between starting Mounjaro and noticing hair changes, this does not necessarily confirm a causal relationship. Further research and long-term observational data are needed to fully characterise any potential link.

If you experience hair loss while taking Mounjaro and are concerned, you should report this to your healthcare provider. You can also report suspected side effects directly to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Why Rapid Weight Loss May Lead to Hair Thinning

The most plausible explanation for hair loss in people taking Mounjaro relates to the rapid and significant weight reduction the medication facilitates. Substantial weight loss—regardless of the method—is a recognised trigger for a specific type of hair loss called telogen effluvium.

Telogen effluvium occurs when a significant physiological stressor causes a large number of hair follicles to prematurely enter the telogen (resting) phase of the hair growth cycle. Normally, approximately 85-90% of scalp hairs are in the active growth phase (anagen), with only 10-15% in the resting phase. Following a metabolic stressor, this ratio can shift dramatically, with many follicles synchronously entering telogen. Two to three months later, these hairs are shed simultaneously, resulting in noticeable thinning.

Rapid weight loss constitutes a metabolic stress that can trigger this response. When the body experiences significant caloric restriction and rapid fat loss, it may prioritise essential physiological functions over non-essential processes like hair growth. Research suggests that rapid or substantial weight loss increases the risk of telogen effluvium, with the British Association of Dermatologists noting that significant dietary restriction is a common trigger.

Clinical studies of Mounjaro demonstrate significant weight loss over the treatment period, which, whilst clinically beneficial for metabolic health, represents a substantial physiological change. This magnitude of weight reduction aligns with known triggers for temporary hair shedding.

Fortunately, telogen effluvium is typically self-limiting and reversible. Once the body adapts to its new metabolic state and weight stabilises, hair follicles generally return to their normal growth cycle, with regrowth typically visible within 6-12 months. Understanding this mechanism helps contextualise hair changes as a potential consequence of successful weight loss rather than direct drug toxicity.

Other Factors That May Contribute to Hair Loss During Treatment

Beyond rapid weight loss itself, several related factors may contribute to hair thinning in individuals taking Mounjaro, making it essential to consider the broader clinical picture.

Nutritional factors represent a significant concern. Mounjaro's appetite-suppressing effects and gastrointestinal side effects may lead to reduced food intake. Hair follicles require adequate protein, iron, zinc, biotin, and vitamins (particularly B vitamins, vitamin D, and vitamin E) for optimal function. Insufficient intake of these nutrients—particularly protein and iron—can compromise hair health. People experiencing persistent nausea or significantly reduced appetite may inadvertently consume inadequate nutrients to support normal hair growth.

Pre-existing medical conditions may also play a role. Many individuals prescribed Mounjaro have type 2 diabetes, which itself is associated with various complications that can affect hair health, including microvascular changes and chronic inflammation. Additionally, conditions such as thyroid disorders, polycystic ovary syndrome (PCOS), and anaemia—which may coexist with obesity and diabetes—are independent causes of hair loss.

Psychological stress associated with lifestyle changes, medication initiation, or managing chronic conditions can contribute to telogen effluvium. The body does not distinguish between physical and psychological stressors when triggering hair follicle changes.

Hormonal fluctuations accompanying significant weight loss may also influence hair growth. Adipose tissue plays an active role in hormone metabolism, and substantial fat loss can alter hormone levels that may affect hair follicles, though this relationship is complex and not fully characterised.

Finally, age and genetic predisposition to hair thinning (such as androgenetic alopecia) may coincidentally manifest during Mounjaro treatment, creating a temporal association that does not reflect causation. A comprehensive assessment considering all these factors is essential for accurate diagnosis and appropriate management.

When to Seek Medical Advice About Hair Loss

Whilst mild hair shedding during significant weight loss may be expected and self-limiting, certain circumstances warrant medical evaluation to exclude other causes and ensure appropriate management.

You should contact your GP if you experience:

• Sudden or severe hair loss, particularly if it occurs in patches rather than diffuse thinning, which may suggest alopecia areata or other specific conditions

• Hair loss accompanied by scalp symptoms such as redness, scaling, itching, pain, or visible inflammation, which could indicate dermatological conditions requiring treatment

• Progressive hair thinning that continues beyond six months or worsens over time, rather than stabilising or improving

• Hair loss associated with other concerning symptoms such as unexplained fatigue, cold intolerance, weight changes beyond expected, menstrual irregularities, or mood changes, which may indicate thyroid dysfunction or other endocrine disorders

• Signs of nutritional deficiency, including brittle nails, dry skin, mouth ulcers, or unusual fatigue

Your GP can perform a thorough assessment including medical history, physical examination of the scalp and hair, and potentially blood tests to evaluate:

• Full blood count (to assess for anaemia)

• Ferritin levels (iron stores)

• Thyroid function tests (TSH, free T4)

• Vitamin B12 and folate

• Vitamin D levels

• Zinc levels if clinically indicated

If you take biotin supplements, inform your doctor before blood tests as biotin can interfere with certain laboratory assays, including thyroid function tests.

Your GP may refer you to a dermatologist if there is suspicion of scarring alopecia, extensive alopecia areata, or persistent diffuse hair loss despite correction of reversible causes.

This evaluation helps distinguish between telogen effluvium related to weight loss and other treatable causes of hair loss. Early identification of nutritional deficiencies or underlying medical conditions enables prompt intervention and may prevent prolonged or permanent hair changes. Your healthcare team can also review your Mounjaro treatment plan and discuss whether any adjustments might be beneficial whilst maintaining the therapeutic benefits of the medication.

Managing and Preventing Hair Loss While Taking Mounjaro

Several evidence-based strategies can help minimise hair loss risk and support hair health during Mounjaro treatment, focusing primarily on nutritional optimisation and overall wellness.

Nutritional strategies form the cornerstone of prevention:

• Ensure adequate protein intake: Hair is primarily composed of keratin, a protein, and insufficient protein intake directly compromises hair structure. Include lean meats, fish, eggs, dairy, legumes, and plant-based protein sources in your diet. If you're concerned about your protein intake, consider consulting a registered dietitian.

• Maintain iron sufficiency: Include iron-rich foods such as red meat, poultry, fish, fortified cereals, spinach, and pulses. Vitamin C enhances iron absorption, so combine iron sources with citrus fruits or vegetables.

• Consider a balanced multivitamin: If your food intake is significantly reduced, discuss with your healthcare provider whether a comprehensive supplement might be appropriate. Individual supplements should generally only be taken if a specific deficiency is identified.

• Stay well-hydrated: Adequate fluid intake supports overall metabolic function and nutrient delivery to hair follicles.

Lifestyle measures also contribute to hair health:

• Manage stress: Incorporate stress-reduction techniques such as mindfulness, regular physical activity, or relaxation exercises

• Gentle hair care: Avoid excessive heat styling, tight hairstyles, and harsh chemical treatments during periods of active weight loss

• Gradual dose escalation: Following the recommended titration schedule for Mounjaro may help your body adapt more gradually to metabolic changes

Regular monitoring with your healthcare team ensures early detection of nutritional deficiencies or other issues. Do not stop or change your Mounjaro dose without consulting your prescriber, but do discuss any concerns about nutrition or side effects.

If hair loss does occur, remember that telogen effluvium is typically temporary. Maintaining optimal nutrition and overall health whilst continuing beneficial treatment creates the best conditions for hair regrowth once your weight stabilises. Decisions about continuing treatment should be made through shared decision-making with your healthcare provider, considering both the benefits of improved metabolic health and any side effects you may experience.

Frequently Asked Questions